Evidence map›Paper›PMID 40713683›Full record

ArticleJournal of nanobiotechnology2025

Bandgap-engineered proteinic near-infrared nanodots for localized precision cancer theranostics.

Mou Seung Kim, In Ho Nam, Hyung Joon Cha, Yun Kee Jo

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mou Seung KimDepartment of Biomedical Convergence Science and Technology, Advanced Institute of Science and Technology, Kyungpook National University, Daegu, 41566, Republic of Korea.
In Ho NamDivision of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea.
Hyung Joon ChaDivision of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea. hjcha@postech.ac.kr.
Yun Kee JoDepartment of Biomedical Convergence Science and Technology, Advanced Institute of Science and Technology, Kyungpook National University, Daegu, 41566, Republic of Korea. ykjo@knu.ac.kr.

Funding

Korean Fund for Regenerative Medicine (KFRM) 23A0105L1National Research Foundation of Korea RS-2023-00209279
6 · The paper itself

Abstract

Silver sulfide (Ag2S) quantum dots hold tremendous potential as promising near-infrared (NIR) theranostic agents for cancer treatment owing to their exceptional photophysical properties and deep tissue penetration capabilities. However, their complex synthesis process under harsh reaction conditions and poor retention at the target site still restrict clinical applications. Herein, metalloprotein adhesive nanodots biomineralized using engineered silver-binding mussel protein (MAP-AgP35) are presented as biosafe, high-performance photosensitizers to enable NIR-triggered theranostics for local cancer treatments. By constructing donor-acceptor pairs within the nanostructures through interfacial adhesive bridging between the MAP-AgP35 and Ag2S minerals, the sticky proteinic Ag2S nanodots dramatically reduced the energy bandgap for enhanced light absorption; this enables remarkably efficient superoxide radical (·O2−) generation and photothermal conversion (η ~ 59%), in addition to effective fluorescence emission in the second NIR (NIR-II) region. The outstanding optochemical functionalities of these nanodots allow direct eradication of cancer cells via effective photodynamic and photothermal actions in the presence of an 808 nm NIR laser, with good biocompatibility toward normal cells. Importantly, these biomineralized nanodots overcome major limitations of conventional photosensitizers, offering a clinically translatable theranostic platform for realizing precise and complete ablation of cancer in a minimally invasive manner.

Indexed as

NeoplasmsQuantum DotsSilver CompoundsTheranostic NanomedicineAnimalsCell Line, TumorHumansInfrared RaysPhotochemotherapyPhotosensitizing AgentsProtein EngineeringPhotosensitizing AgentsSilver Compoundssilver sulfideBandgap engineeringBiomineralizationBiosafe quantum dotsNear-infrared theranosticsProteinic Ag2S nanodots

Identifiers

PMID40713683
PMCPMC12296602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.